

BIOGRAPHICAL SKETCH

NAME: Marinella Clerico

POSITION TITLE: Associate Professor of Neurology, University of Torino-Italy

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	Completion Date	FIELD OF STUDY
G.B. Vasco High school, Mondovi, Italy	High school degree	07/1994	Scientific field
University of Torino, Torino, Italy	Medical school degree	11/2001	Medicine and surgery fields. The last two years were almost entirely dedicated to neurology field. During the internal fellowship I conducted my thesis on Myasthenia Gravis.
University of Torino, Torino, Italy	Neurology residency board	12/2006	Neurology, in particular Neuroimmunology (Multiple Sclerosis)
University of Torino, Torino, Italy	Biomedical Sciences end Human Oncology PhD	07/2010	Multiple sclerosis

A. Personal Statement

I have been working in Multiple Sclerosis (MS) field for over ten years. As responsible of the neuroimmunology section, I have a wide experience in MS diagnostic and treatment field and is a researcher in many multicentric international neuroimmunological and clinical trials. I coordinate international research groups on MS. I published over 30 papers on peer-reviewed journal and contributed with about one-hundred posters and oral communications to many international and national congresses.

Since the fourth year of Medical School I have been involved in the clinical and immunological research in the neuroimmunology field. My Medical Degree thesis was on the T-cell receptor restriction in patients diagnosed with Myasthenia Gravis.

During my neurology residency I was involved in the clinical care of patients with MS and in several Clinical Trials (phase II and III trials, independent spontaneous trials) with different drugs for the treatment of MS as treating/ evaluating neurologist. During my third year of residency I started a research fellowship (January 2005-July 2005) at the MS center of the University of California San Francisco (UCSF), where I conducted different clinical research project and I attended, as observer, to the outpatient Clinical practice with MS patients of my mentor, Prof. Douglas Goodin.

Since May 2004 to now I am part of the "Cochrane Multiple Sclerosis and Rare Disease of the CNS" organization and to now I have been author of two Cochrane metanalyses aimed to investigate the efficacy of first line therapy in CIS patients. Both my residency thesis as well as my PhD thesis were focused on a Cochrane metanalysis on the field of MS (CIS therapy).

Since the years of medical school I started to have an high interest in and to perform laboratory research on Neuroimmunology and more lately, since 2009, more driven to MS, My MS lab interest and experience is in the fields of Immunology, Molecular biology and Bioinformatic.

All my scientific interests, particularly in the MS field are well documented by the publications I listed below.

Furthermore I am ad hoc Reviewer for several scientific journals, including European Journal of Neurology, Neurological Sciences, and 2010 to now I have served as ad hoc reviewer for the following Scientific Societies: Italian Multiple Sclerosis Foundation (FISM).

I took part to several meetings (both academy-based and sponsored) as Invited Speaker as well as to Advisory Boards for Pharmaceutical Companies (Sanofi Genzyme, Merck Serono)

I have been Thesis Supervisor for more than 30 Medical Degree students, five Bachelor in Adapted physical activities, one PhD student, and for one Neurology Residents

B. Positions and Honors

Positions and Honors					
Institution	Division/research group	Location	Position	From year	To year
University of Torino, Torino, Italy	Division of Neurology, Clinical and biological Sciences Department	San Luigi Gonzaga University Hospital	Associate Professor	2018	To now
				2019	To now
			Neurology Unit		

			Chief		
University of Torino, Torino, Italy	Division of Neurology, Clinical and biological Sciences Department	San Luigi Gonzaga University Hospital	MS and autoimmune diseases Centre Responsible	2012	To now
University of Torino, Torino, Italy	Division of Neurology, Clinical and biological Sciences Department	San Luigi Gonzaga University Hospital	Assistant Professor	2012	To February 28th, 2018
University of Torino, Torino, Italy	Division of Neurology	San Luigi Gonzaga University Hospital	Post- DoctoralFellowship	2010	2012
	Federazione Italiana Sclerosi Multipla (FISM)		Referee	2010	To now
University of Torino, Torino, Italy	Division of Neurology	San Luigi Gonzaga University Hospital	PhDStudent	2007	2010
	Cochrane Multiple Sclerosis and Rare Disease of the CNS" as part of the Cochrane Collaboration		Membership	2004	To now
University of Torino, Torino, Italy	Division of Neurology	Città della Salute e della Scienza Hospital, Torino (From 2001 to 2003) San Luigi Gonzaga University Hospital (From 2004 to 2006)	Resident in Neurology	2001	2006
	Italian Neurological Society		Membership	2001	To now

B. Contributions to Science

Contribution to science is listed by the following selected peer-reviewed publications

H-index: 18

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. *Lancet Neurol*. 2019 Jan 25. pii: S1474-4422(18)30392-2. doi: 10.1016/S1474-4422(18)30392-2. [Epub ahead of print] PubMed PMID: 30692052.

Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M. Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis. *Front Immunol*. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018. PubMed PMID: 30671056; PubMed Central PMCID: PMC6331474.

Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D'Ovidio F, Bombaci A, Bersano E, Mazzini L, Mora G, Chiò A; Piemonte and Valle d'Aosta Register for ALS (PARALS). Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. *J Neurol Neurosurg Psychiatry*. 2019 Jan 10. pii: jnnp-2018-319611. doi: 10.1136/jnnp-2018-319611. [Epub ahead of print] PubMed PMID: 30630957.

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. *J Neurol Neurosurg Psychiatry*. 2018 Nov 2. pii: jnnp-2018-319208. doi: 10.1136/jnnp-2018-319208 [Epub ahead of print] PubMed PMID: 30389778.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S. e-Health and multiple sclerosis: An update. *Mult Scler.* 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19. PubMed PMID: 30231004.

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP; On behalf of the iMUST Group. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. *Mult Scler.* 2018 Jul 25;1352458518790390. doi: 10.1177/1352458518790390.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, **Clerico M**. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. *J Neuroimmunol.* 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17. PubMed PMID: 29153614.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, **Clerico M**, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. *Neurology.* 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1. PubMed PMID: 29093064.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. *Expert Opin Drug Saf.* 2017 Jul 5;1-10. doi:10.1080/14740338.2017.1346082. [Epub ahead of print] PubMed PMID: 28641055.

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. *MultScler.* 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1. PubMed PMID: 28290755.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L. Natalizumab in Multiple Sclerosis: Long-Term Management. *Int J Mol Sci.* 2017 Apr 29;18(5). pii: E940. doi: 10.3390/ijms18050940. Review. PubMed PMID: 28468254.

Filippini G, Del Giovane C, **Clerico M**, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. *Cochrane Database Syst Rev.* 2017 Apr 25;4:CD012200. doi:10.1002/14651858.CD012200.pub2. Review. PubMed PMID: 28440858.

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. *Neurology.* 2017 Mar 21;88(12):1144-1152. doi:10.1212/WNL.0000000000003740. Epub 2017 Feb 22. PubMed PMID: 28228569.

Lugaresi Alessandra, De Robertis Francesca, **Clerico Marinella**, Brescia Morra Vincenzo, Centonze Diego, Borghesan Stefano, Maniscalco Giorgia Teresa (2016). Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β -1a using an electronic device: the RIVER study. *EXPERT OPINION ON DRUG DELIVERY*, vol. 13, p. 931-935, ISSN: 1742-5247, doi:10.1517/17425247.2016.11480292 2016

Filippini Graziella, **Clerico Marinella**, Beiki Omid, Mattoscio Miriam, Piazza Federico, Del Giovane Cinzia, Fredrikson Sten, Tramacere Irene, Scalfari Antonio (2016). Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. *COCHRANE DATABASE OF SYSTEMATIC REVIEWS*, vol. 2016, p. 1-16, ISSN:1469-493X, doi: 10.1002/14651858.CD012200 3 2016

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Bar, **Clerico M** [...] Vernino S, Nations S, Meyer D, Gorham N (2016). Randomized trial of thymectomy in myasthenia gravis. *NEW ENGLAND JOURNAL OF MEDICINE*, vol. 375, p. 511-522, ISSN: 0028-4793, doi: 10.1056/NEJMoa16024894 2016

De Mercanti Stefania, Rolla Simona, Cucci Angele, Bardina Valentina, Cocco Eleonora, Vladic Anton, Soldo-Butkovic Silva, Habek Mario, Adamec Ivan, Horakova Dana, Annovazzi Pietro, Novelli Francesco, Durelli Luca, **Clerico Marinella** (2016). Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. *NEUROLOGY@NEUROIMMUNOLOGY & NEUROINFLAMMATION*, vol. 3, p. 1-8, ISSN: 2332-7812, doi: 10.1212/NXI.000000000000194 5 2016

Calvo Andrea, Canosa Antonio, Bertuzzo Davide, Cugnasco Paolo, Solero Luca, **Clerico Marinella**, Mercanti Stefania De, Bersano Enrica, Cammarosano Stefania, Ilardi Antonio, Manera Umberto, Moglia Cristi [...] . Influence of cigarette smoking on ALS outcome: A population-based study. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, vol.87, p. 1229-1233-1233, ISSN: 0022-3050, doi: 10.1136/jnnp-2016-3137936 2015

Barbero P, Busso M, Tinivella M, Artusi Ca, De Mercanti S, Cucci A, Veltri A, Avagnina P, Calvo A, Chio' A, Durelli L, **Clerico M.** (2015). Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. JOURNAL OF NEUROLOGY, vol. 262, p. 2662-2667, ISSN: 0340-5354, doi: 10.1007/s00415-015-7894-17 2015

A. Chiò, A. Calvo, G. Bovio, A. Canosa, D. Bertuzzo, F. Galmozzi, P. Cugnasco, **M. Clerico**, S. De Mercanti, E. Bersano, S. Cammarosano, A. Ilardi, U. Manera, C. Moglia, R. Sideri, K. Marinou, E. Bottacchi, F. Pisano, R. Cantello, L. Mazzini, G. Mora Piemonte, V. d. Register (2014). Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA NEUROLOGY, vol. 71, p. 1134-1142, ISSN: 2168-6149, doi: 10.1001/jamaneurol.2014.11299 2014

Marinella Clerico, Irene Schiavetti, Stefania F. De Mercanti, Federico Piazza, Dario Gned, Vincenzo Brescia Morra, Roberta Lanzillo, Angelo Ghezzi, Anna Bianchi, Giuseppe Salemi, Sabrina Realmuto, Patrizia Sola, Francesca Vitetta, Paola Cavalla, Damiano Paolicelli, Maria Trojano, Maria Pia Sormani, Luca Durelli (2014). Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab. JAMA NEUROLOGY, vol. 71, p. 954-960, ISSN: 2168-6149, doi: 10.1001/jamaneurol.2014.1200 10 2014

S. Rolla, V. Bardina, S. De Mercanti, P. Quaglino, R. De Palma, D. Gned, D. Brusa, L. Durelli, F. Novelli, **M. Clerico** (2014). Th22 cells are expanded in multiple sclerosis and are resistant to IFN- γ . JOURNAL OF LEUKOCYTE BIOLOGY, vol. 96, p. 1155-1164, ISSN: 0741-5400, doi:10.1189/jlb.5A0813-463RR11 2014

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, **Clerico M**, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR (2014). Epigenetic therapy for Friedreich ataxia. ANNALS OF NEUROLOGY, vol. 76, p. 489-508, ISSN: 0364-5134, doi: 10.1002/ana.24260

Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, **Clerico M**, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A, for the BRIDGE study group (2012). Patient adherence to and tolerability of self-administered interferon β -1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC NEUROLOGY, vol. 12, p. 1-10, ISSN: 1471-2377, doi: 10.1186/1471-2377-12-7 18 2012

Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, Silvennoinen O, Niccolai E, Amedei A, Ivaldi F, **Clerico M**, Contessa G, Uccelli A, Durelli L, Novelli F. (2012). Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN- γ R2. JOURNAL OF IMMUNOLOGY, vol. 188, p. 1011-1018, ISSN: 0022-1767, doi:10.4049/jimmunol.1004013 19 2011

Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M, French-Italian Mitoxantrone Interferon-beta-1b Trial Group (including: Trojano M, Paolicelli D, D'Onghia M, Rumbach L, Clavelou P, Aufauvre D, **Clerico M** [...] beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, vol. 82, p. 1344-1350, ISSN: 0022-3050, doi: 10.1136/jnnp.2010.229724 20 2011

Cucci A, Barbero P, **Clerico M**, Ferrero B, Versino E, Contessa G, Demercanti S, Viglietta E, Di Liberto A, Vai AG, Durelli L (2010). PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE. JOURNAL OF NEUROIMMUNOLOGY, vol. 226, p. 150-157, ISSN: 0165-5728 22 2010

Simona Rolla, Laura Conti, Raffaele De Palma, Daniela Boselli, Valentina Bardina, Gabriella Rodolico, Olli Silvennoinen, **Marinella Clerico**, Luca Durelli, Francesco Novelli (2010). In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN- γ R2 chain. CYTOKINE, vol. 52, p. 86-87, ISSN: 1043-4666 23 2009

L Durelli, L Conti, **M Clerico**, D Boselli, G Contessa, P Ripellino, B Ferrero, P Eid, F Novelli (2009). T helper 17 cells expand in multiple sclerosis and are inhibited by interferon- β . ANNALS OF NEUROLOGY, vol. 65(5), p. 499-509, ISSN: 0364-5134 24 2009

Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, **Clerico M**, OPTIMS Trial NAb Sub-Study Group (2009). Neutralizing antibodies in multiple sclerosis patients treated with 375 MCG INTERFERON- β -1b. EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 9, p. 387-397, ISSN: 1471-2598 25 2009

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, **Clerico M** [...] multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 286, p. 109-113, ISSN: 0022-510X, doi: 10.1016/j.jns.2009.06.036 26 2009

Citterio A, Beghi E, Millul A, Evoli A, Mantegazza R, Antozzi C, Baggi F, Cornelio F, Durelli L, **Clerico M**, Piccolo G, Cosi V (2009). Risk factors for tumor occurrence in patients with myasthenia gravis. JOURNAL OF NEUROLOGY, vol. 256, p. 1221-1227, ISSN: 0340-5354, doi: 10.1007/s00415-009-5091-9 27 2009

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, **Clerico M**, [...] abase Network (MSDN) Group (2009). Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. ANNALS OF NEUROLOGY, vol. 66, p. 513-520, ISSN: 0364-5134, doi: 10.1002/ana.21757 28 2009

Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L (2008). Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 3, p. 1-12, ISSN: 1469-493X 31 2008

Clerico M, RIVOIRO C, CONTESSA G, VIGLIETTI D, DURELLI L (2008). The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug A critical evaluation based upon evidence based parameters and published systematic reviews. CLINICAL NEUROLOGY AND NEUROSURGERY, vol. -, p. 878-885, ISSN: 0303-8467 32 2008

L. Durelli, P. Barbero, M. Bergui, E. Versino, M. A. Bassano, E. Verdun, C. Rivoiro, C. Ferrero, E. Picco, P. Ripellino, G. Giuliani, E. Montanari, **M. Clerico** (2008). MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, vol. 79, p. 646-651, ISSN: 0022-3050 33 2008

Luca Durelli, Pierangelo Barbero, Mauro Bergui, Elisabetta Versino, Marco A. Bassano, Elisabetta Verdun, Bruno Ferrero, Chiara Rivoiro, Cinzia Ferrero, Elisabetta Picco, Paolo Ripellino, Daniela Viglietti, Giorgio Giuliani, Enrico Montanari, **Marinella Clerico**, the OPTIMS Study Group (2008). The OPTimization of Interferon for MS Study: 375 μ g interferon beta-1b in suboptimal responders. JOURNAL OF NEUROLOGY, vol. 255, p. 1315-1323, ISSN: 0340-5354 34 2008

C. Rivoiro, R. Barbero, A. Cucci, G. Contessa, C. Ferrero, M. Bergui, E. Versino, B. Ferrero, G. Giuliani, E. Montanari, M. Clerico (2007). Is the combination of different treatment response indicators useful to identify patients with a sub-optimal response to interferon beta?. JOURNAL OF NEUROLOGY, vol. 254, ISSN: 0340-5354 36 2007

Clerico M, G. CONTESSA, DURELLI L (2007). INTERFERON-beta 1A; 1A FOR THE TREATMENT OF MULTIPLE SCLEROSIS. EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 7(4), p. 535-542, ISSN: 1471-2598 37 2007

Clerico Marinella, Barbero Pierangelo, Contessa Giulia, Ferrero Cinzia, Durelli Luca (2007). Adherence to interferon-beta treatment and results of therapy switching. JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 259, p. 104-108, ISSN: 0022-510X, doi: 10.1016/j.jns.2006.05.075 38 2007

DURELLI L, P. BARBERO, **Clerico M** (2006). A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. NEUROLOGY, vol. 67, p. 2264-2265, ISSN: 0028-3878 41 2006

Ristori G, Cannoni S, Stazi Ma, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C, Bomprezzi R, Di Giovanni S, Talamanca Lf, Nistico L, Fagnani C, Neale Mc, Cascino I, Giorgi G, **Clerico M** [...] in C., Freo U., Zaffaroni M., Ghezzi A., Falcone N. (2006). Multiple sclerosis in twins from continental Italy and Sardinia: A nationwide study. ANNALS OF NEUROLOGY, vol. 59, p. 27-34, ISSN: 0364-5134 42 2006

BARBERO P, BERGUI M, VERSINO E, RICCI A, ZHONG JJ, FERRERO B, **Clerico M**, PIPIERI A, VERDUN E, GIORDANO L, DURELLI L (2006). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. MULTIPLE SCLEROSIS, vol. 12, p. 72-76, ISSN: 1352-4585 43 2006

D. Additional Information: Research Support and/or Scholastic Performance

Dr. Clerico has been working in Multiple Sclerosis (MS) field for over ten years. As responsible of the neuroimmunology section, she has a wide experience in MS diagnostic and treatment field and is a researcher in many multicentric international neuroimmunological and clinical trials. She coordinates international research groups on MS. She published over 30 papers on peer-reviewed journal and contributed with about one-hundred posters and oral communications to many international and national congresses.

- Selection of studies as principal investigator:
 - REVEAL Study supported by BIOGEN IDEC from June 2015 to November 2015
 - "REGISTRO ITALIANO SCLEROSI MULTIPLA-REGISTRO SM001 E REGISTRO SM002" study supported by Fondazione Italiana Sclerosi Multipla-FISM Onlus and University "Aldo Moro" of Bari since November 2016 to now.
 - "Studio del microbiota intestinale nello sviluppo della Sclerosi Multipla" supported by Clinical and biological Sciences Department, University of Turin since November 2016 to now.
 - "Studio osservazionale longitudinale in pazienti affetti da Sclerosi Multipla recidivante remittente (SMRR) dopo 24 somministrazioni di Natalizumab" supported by Clinical and biological Sciences Department, University of Turin since November 2016 to now.
 - "Identificazione di nuovi marcatori epigenetici nella sclerosi multipla" study supported by Clinical and biological Sciences Department, University of Turin since November 2016 to now.
- ECTRIMS video highlights selected paper during last ECTRIMS annual meeting, London 2016.
- Recipient of FISM grant in the project entitled "MS and Microbiota"

Turin, July, 15th 2019

